PepGen Reports Favorable Safety and Splicing Trends for PGN-EDODM1 in Lowest Dose DM1 Trial
PEPG has more than doubled off its 52-week low of $0.88 on elevated volume (2.3× avg).
Summary
PepGen reported positive safety and promising splicing correction data from the lowest dose of its lead DM1 drug candidate, PGN-EDODM1, supporting continued development and extending its cash runway.
Key Events · Product Development and Regulatory · PEPG
-
Favorable Safety Profile
PGN-EDODM1 was generally well-tolerated in the 5 mg/kg cohort, with all adverse events reported as mild or moderate and no serious adverse events.
-
Promising Splicing Correction
The study showed a mean splicing correction of 7.3% (n=6) compared to placebo, with a more significant 22.9% correction observed when excluding one outlier patient (n=5).
-
Positive vHOT Trends
Promising trends were observed in the video hand opening test (vHOT) in the treatment group, suggesting potential functional benefits at higher doses.
-
Extended Cash Runway
The company expects its current cash to fund operations into the second half of 2027, providing financial stability for ongoing development.
Analysis · PEPG · Life Sciences
PepGen Inc. announced promising topline results from the lowest dose cohort of its Phase 2 FREEDOM2-DM1 trial. The lead candidate, PGN-EDODM1, demonstrated a favorable safety profile with all adverse events reported as mild or moderate and no serious adverse events. Crucially, the study showed a mean splicing correction of 22.9% (excluding one outlier) and promising trends in vHOT, supporting the drug's mechanism of action. While functional improvements were not observed at this lowest dose, the positive safety and biological activity data are significant, especially following the company's recent challenges including a partial clinical hold and a discontinued program. This data provides a critical positive signal for the ongoing development of their key remaining asset and extends their cash runway into 2H 2027. Investors will now focus on the upcoming 10 mg/kg cohort data in 2H 2026.
At the time of this filing, PEPG was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $292.4M. The 52-week trading range was $0.88 to $7.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.